Arrowhead Research Corporation
Compare this stock
ARWR Stock Report Card
$
36%
Performance
Score:
10/100
ARWR returned -18.45% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
63/100
4 analysts offer 12-month price targets for ARWR. Together, they have an average target of 63.86, the most optimistic target put ARWR at 90 within 12-months and the most pessimistic has ARWR at 31.
Technicals
Score:
64/100
ARWR receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
Score:
10/100
ARWR has missed earnings 16 times in the last 20 quarters.
Profit
Score:
24/100
Out of the last 20 quarters, ARWR has had 6 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
Score:
50/100
ARWR has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
Arrowhead Research Corporation Summary
Nasdaq / ARWR
Healthcare
Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ARWR scored poorly on our reportcard. Here are some similar companies and how they performed.